Overview

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the visual outcome and number of injections required during an optical coherence tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular age-related macular degeneration (NVAMD).
Phase:
N/A
Details
Lead Sponsor:
Brian Burke, MPH
MidAtlantic Retina
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept